Endometrial metastasis of a primitive neuroendocrine ovarian carcinoma: management and treatment of a case

Background: Neuroendocrine tumours are a heterogeneous group of separate clinico-pathological entities which have a common characteristic, i.e., expression of potential endocrine differentiation. In the ovary, the term "neuroendocrine" relates mainly to widely known carcinoids, but it may also be applied to rare neuroendocrine carcinomas as non-small cell type and small cell carcinomas of pulmonary type. In the literature only 11 cases of primary ovarian non-small cell neurendocrine carcinomas have been described and ten of these were associated with a surface epithelial ovarian turnout. Small cell neuroendocrine carcinoma of the ovary is a rare malignant tumour of the ovary. Advanced small cell carcinoma of the ovary is a very aggressive tumour with an overall poor prognosis and unfavourable outcome. Case report: The case reported is unique in the literature because the authors describe a rare case of endometrial metastasis of a primary ovarian non-small cell neurendocrine carcinoma without any surface epithelial ovarian tumour association. The tumour invaded up to less than half of the myometrium. The first symptoms were related to endometrial metastasis as metrorrhagia and pelvic pain while the asymptomatic presence of primary ovarian carcinoma was not acknowledged with physical examination, routine biochemistry, turnout markers, blood count and traditional transvaginal greyscale ultrasound. Conclusion: Magnetic resonance and three-dimensional (3D) ultrasonography with power Doppler are a great help in the diagnosis of ovarian localisation but only immunohistochemistry on histological material can provide a correct diagnosis. Immunohistochemistry expression of Ki67 is a useful marker of malignancy. Due to the rarity of this neoplasm, a general consensus for optimal treatment has yet to emerge. The reported biological aggressiveness of these tumours prompts combined treatment with radical surgery and adjuvant polychemotherapy.

Neuroendocrine ovarian tumours; Endometrial metastasis

[1] Kupryjanczyk J.: “Neuroendocrine tumors of the ovary-a review”. Verh. Dtsch. Ges. Pathol., 1997, 81, 253.

[2] Eichhorn J.H., Young R.H.: “Neuroendocrine tumors of the genital tract”. Am. J. Clin. Pathol., 2001, 115 (suppl. 1), S94.

[3] Collins R.J., Cheung A., Ngan H.Y.S., Wong L.C., Chan S.Y.W., Ma H.K.: “Primary mixed neuroendocrine and mucinous carcinoma of the ovary”. Arch. Gynecol. Obstet., 1991, 248 (suppl. 1), 139.

[4] Khurana K.K., Tornos C., Silva E.G.: “Ovarian neuroendocrine carcinoma associated with a mucinous neoplasm”. Arch. Pathol. Lab. Med., 1994, 118, 1032.

[5] Jones K., Diaz J.A., Donnor L.R.: “Neuroendocrine carcinoma arising in an ovarian mucinous cystadenoma”. Int. J. Gynecol. Pathol., 1996, 15, 167.

[6] Eichhorn J.H., Lawrence W.D., Young R.H., Scully R.E.: “Ovarian neuroendocrine carcinoma of non-small cell type associated with surface epithelial adenocarcinomas”. Int. J. Gynecol. Pathol., 1996, 15, 303.

[7] Chen K.T.K.: “Composite large-cell neuroendocrine carcinoma and surface epithelial - stromal neoplasm of the ovary”. Int. J. Surg. Pathol., 2000, 8, 169.

[8] Behnam K., Kabus D., Behnam M.: “Primary ovarian undifferentiated non small cell carcinoma, neurendocrine type – case report”. Gynecol. Oncol., 2004, 92, 372.

[9] Young R.H., Oliva E., Scully R.E.: “Small cell carcinoma of the ovary, hypercalcemic type”. Am. J. Surg. Pathol., 1994, 18, 1102.

[10] Chen L., Dinh T.A., Haque A.: “Small cell carcinoma of the ovary with hypercalcemia and ectopic parathyroid hormone production”. Arch. Pathol. Lab. Med., 2005, 129, 531.

[11] Diaz-Montes T.P., Rosenthal L.E., Bristow R.E., Grumbine F.C.: “Primary insular carcinoid of the ovary”. Gynecol. Oncol., 2006, 101, 175 (Epub. Nov. 18, 2005 ).

[12] Sholler G.L., Luks F., Mangray S., Meech S.J.: “Advanced small cell carcinoma of the ovary in a pediatric patient with long-term survival and review of the literature”. J. Pediatr. Hematol. Oncol., 2005, 27, 169.

[13] Kurjak A., Prka M., Arenas J.M., Sparac V., Merce L.T., Corusic A., Ivancic-Kosuta M.: “Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic periand postmenopausal women”. Croat. Med. J., 2005, 46, 757.

[14] Kurjak A., Kupesic S., Sparac V., Prka M., Bekavac I.: “The detection of Stage I ovarian cancer by three-dimensional sonography and power Doppler”. Gynecol. Oncol., 2003, 90, 258.

[15] Cohen L.S., Escobar P.F., Scharm C., Glimco B., Fishman D.A.: “Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction”. Gynecol. Oncol., 2001, 82, 40.

[16] Kurjak A., Kupesic S., Sparac V., Kosuta D.: “Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions”. Ultrasound Obstet Gynecol., 2000, 16, 365.

[17] Sparac V., Kupesic S., Kurjak A.: “What do contrast media add to three-dimensional power Doppler evaluation of adnexal masses?”. Croat. Med. J., 2000, 41, 257.

[18] Weber G., Merz E., Bahlmann F., Macchiella D.: “Ultrasound assessment of ovarian tumors-comparison between transvaginal 3D technique and conventional 2-dimensional vaginal ultrasonography”. Ultraschall Med., 1997, 18, 26.